Brokerages predict that DexCom, Inc. (NASDAQ:DXCM) will post earnings of $0.71 per share for the current quarter, according to Zacks. Eleven analysts have made estimates for DexCom’s earnings, with estimates ranging from $0.38 to $0.89. DexCom reported earnings of $0.54 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 31.5%. The firm is expected to report its next quarterly earnings report on Thursday, February 20th.
On average, analysts expect that DexCom will report full-year earnings of $1.42 per share for the current year, with EPS estimates ranging from $1.25 to $1.60. For the next fiscal year, analysts expect that the firm will report earnings of $1.78 per share, with EPS estimates ranging from $1.05 to $2.64. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover DexCom.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.45. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The company had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. During the same quarter in the previous year, the firm posted $0.17 earnings per share. The company’s quarterly revenue was up 48.6% compared to the same quarter last year.
A number of equities research analysts have commented on the stock. Jefferies Financial Group increased their price objective on shares of DexCom from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Zacks Investment Research raised DexCom from a “hold” rating to a “buy” rating and set a $154.00 target price on the stock in a report on Friday, October 25th. Guggenheim upgraded DexCom from a “neutral” rating to a “buy” rating in a research note on Thursday, November 7th. ValuEngine cut DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Robert W. Baird upped their price target on DexCom from $195.00 to $240.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $184.33.
Shares of DXCM stock traded up $3.58 during trading hours on Tuesday, reaching $227.50. 144,667 shares of the stock were exchanged, compared to its average volume of 1,413,019. The business’s fifty day moving average is $184.38 and its two-hundred day moving average is $157.40. The firm has a market capitalization of $20.62 billion, a P/E ratio of 758.33 and a beta of 0.76. DexCom has a 12-month low of $105.05 and a 12-month high of $229.69. The company has a debt-to-equity ratio of 1.41, a current ratio of 5.63 and a quick ratio of 5.26.
In other news, SVP Jeffrey Moy sold 4,601 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $149.85, for a total value of $689,459.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Quentin S. Blackford sold 11,686 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $149.86, for a total transaction of $1,751,263.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 77,459 shares of company stock worth $11,852,977. Company insiders own 0.88% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Virtus ETF Advisers LLC purchased a new position in shares of DexCom in the 2nd quarter valued at $29,000. CSat Investment Advisory L.P. bought a new position in shares of DexCom in the second quarter worth about $31,000. Steward Partners Investment Advisory LLC bought a new position in shares of DexCom in the second quarter worth about $31,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of DexCom in the 2nd quarter valued at approximately $37,000. Finally, Assetmark Inc. boosted its stake in shares of DexCom by 120.9% in the 2nd quarter. Assetmark Inc. now owns 285 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 156 shares in the last quarter. 98.20% of the stock is currently owned by institutional investors and hedge funds.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: Why is cost of goods sold important?
Get a free copy of the Zacks research report on DexCom (DXCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.